[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100256581":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":18,"locations":23,"responsibleParty":36,"collaborators":18,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":40,"sex":46,"minAge":47,"maxAge":18,"enrollmentInfo":48,"targetDuration":18,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":18,"overallStatus":57,"whyStopped":18,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"Institut Claudius Regaud","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Solid tumors","Patients with solid tumor starting a intra venous chemotherapy with 21 days cycles.",[12],"Other: Telephone follow-up nursing device",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":18},"Telephone follow-up nursing device","Telephone follow-up nursing device involving:\n\n* telephone appointments made by a dedicated nurse and set up at key stage of treatment (1 phone call per week during chemotherapy cycles),\n* specific questionnaire used by the nurse at each phone call (toxicity, general care, quality of life...),\n* actions taken for the patient following each phone call (consultation with a doctor, patient hospitalization, sending of a prescription, coordination with the city medical caregiver);",[9],null,[20],{"name":21,"affiliation":5,"role":22},"Jean-Pierre DELORD, PhD","PRINCIPAL_INVESTIGATOR",[24],{"facility":25,"status":18,"city":26,"state":18,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":18},"Institut claudius regaud","Toulouse","31059","France","FR",{"type":31,"coordinates":32},"Point",[33,34],1.44367,43.60426,{"lat":34,"lon":33},{"type":37,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100256581","evaluation-of-the-impact-of-a-follow-up-phone-call-nurse-device-in-the-care-of-patients-with-chemotherapy-treatment-100256581",false,"NCT02619045","Evaluation of the Impact of a Follow-up Phone Call Nurse Device in the Care of Patients With Chemotherapy Treatment","Evaluation of the Impact of a Follow-up Phone Call Nurse Device in the Care of Patients With Chemotherapy Treatment, in Their Quality of Life and Medico-economic Analysis of This Follow-up Program Device","EVAL'COACH","Inclusion Criteria:\n\n1. Patient with a solid tumor.\n2. Patient starting a first cycle of chemotherapy (+ - targeted therapy).\n3. Patient starting intravenous chemotherapy including 21-day cycles.\n4. Patient ≥18 years old.\n5. Patient affiliated to a social security system in France.\n6. Patient who signed the informed consent before study inclusion and before any study specific procedure.\n\nExclusion Criteria:\n\n1. Patient already included in another interventional biomedical research.\n2. Patient who began intravenous chemotherapy.\n3. Patient who must receive an oral chemotherapy.\n4. Patient who must be treated with a weekly chemotherapy or with concomitant radiotherapy.\n5. Patient unreachable by phone.\n6. Patient with no caregiver who can answer the phone in his place.\n7. Pregnant or breastfeeding women.\n8. Any psychological condition, family, geographic or social not to comply with medical monitoring and \u002F or procedures in the study protocol.\n9. Patient protected by law.","ALL","18 Years",{"count":49,"type":50},200,"ACTUAL","INTERVENTIONAL",[53],"NA","This study evaluate the Impact of a Follow-up Phone Call Nurse Device in the Care of Patients With Chemotherapy Treatment, in their Quality of Life and Medico-economic Analysis of this Follow-up Program Device.",[56],"Solid Tumors","COMPLETED","2018-03-01",{"date":60,"type":50},"2018-03-02",{"date":62,"type":50},"2015-11-09",{"date":64,"type":50},"2017-06-21",{"name":5,"class":6},1]